Evolus Future Growth

Future criteria checks 6/6

Evolus is forecast to grow earnings and revenue by 66.4% and 23.1% per annum respectively. EPS is expected to grow by 66.4% per annum. Return on equity is forecast to be 33.9% in 3 years.

Key information

66.4%

Earnings growth rate

66.4%

EPS growth rate

Pharmaceuticals earnings growth	23.5%
Revenue growth rate	23.1%
Future return on equity	33.9%
Analyst coverage	Good
Last updated	14 May 2024

Recent future growth updates

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Recent updates

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Earnings and Revenue Growth Forecasts

NasdaqGM:EOLS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	456	47	98	126	7
12/31/2025	348	-13	17	27	7
12/31/2024	263	-44	-24	-18	7
3/31/2024	220	-60	-26	-24	N/A
12/31/2023	202	-62	-36	-34	N/A
9/30/2023	185	-63	-46	-44	N/A
6/30/2023	169	-66	-63	-60	N/A
3/31/2023	156	-72	-70	-67	N/A
12/31/2022	149	-74	-88	-85	N/A
9/30/2022	140	-79	-87	-85	N/A
6/30/2022	132	-79	-101	-100	N/A
3/31/2022	121	-71	-64	-63	N/A
12/31/2021	100	-47	-34	-33	N/A
9/30/2021	86	-139	-27	-27	N/A
6/30/2021	77	-131	-10	-8	N/A
3/31/2021	58	-137	-40	-38	N/A
12/31/2020	57	-163	-61	-58	N/A
9/30/2020	55	-67	-76	-72	N/A
6/30/2020	51	-82	-87	-83	N/A
3/31/2020	45	-99	-107	-102	N/A
12/31/2019	35	-90	-98	-93	N/A
9/30/2019	15	-88	-93	-89	N/A
6/30/2019	2	-73	-73	-70	N/A
3/31/2019	N/A	-52	-43	-43	N/A
12/31/2018	N/A	-47	-26	-26	N/A
9/30/2018	N/A	-30	-15	-15	N/A
6/30/2018	N/A	-21	-12	-12	N/A
3/31/2018	N/A	-7	-10	-10	N/A
12/31/2017	N/A	-4	N/A	-13	N/A
9/30/2017	N/A	-13	N/A	-14	N/A
6/30/2017	N/A	-14	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-14	N/A
12/31/2016	N/A	-20	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EOLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: EOLS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EOLS is expected to become profitable in the next 3 years.

Revenue vs Market: EOLS's revenue (23.1% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: EOLS's revenue (23.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EOLS's Return on Equity is forecast to be high in 3 years time (33.9%)

Evolus Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Recent updates

President recently sold US$204k worth of stock

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus: Turning That Frown Upside Down

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Evolus appoints Experian's exec as CFO

Consensus forecasts updated

Forecast to breakeven in 2024

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022

Insufficient new directors

Evolus Q2 2022 Earnings Preview

Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau

Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials